Published on November 3, 2017
Genetic testing can help physicians to better understand an individual’s AML and help guide treatment decisions. So which genetic tests should AML patients have and when? In this Patient Empowerment Network program, in partnership with The Leukemia & Lymphoma Society (LLS), an expert panel discusses essential genetic testing for AML patients. Dr. Lee Greenberger, Chief Scientific Officer at the LLS is joined by AML specialist Dr. Amit Verma and patient advocate Kuldip Ahluwalia as they explain this complex topic and share tools for patients to help ensure they get the best care.
This was a Patient Empowerment Network program produced by Patient Power, in partnership with The Leukemia & Lymphoma Society (LLS). We thank Astellas, Celgene Corporation, Novartis, Pfizer and Seattle Genetics for their support.